Eniluracil: an irreversible inhibitor of dihydropyrimidine dehydrogenase

Bibliography

• LIU G, FRANSSEN E, FITCH MI, WARNER E: Patient preferences for oral versus intravenous palliative chemotherapy. J. Clin. Oncol (1997) 15(1):110–115.
   PubMed Web of Science ®Google Scholar
• •Patients were asked their preferences for oral or iv. chemotherapy. While most patients preferred oral chemotherapy, the majority were not willing to sacrifice efficacy for their preference.
   Google Scholar
• BRITO RA, MEDGYESY D, ZUKOWSKI TH et al.: Fluoropy-rimidines: a critical evaluation. Oncology (1999) 57(Suppl.
   Google Scholar
• DEMARIO MD, RATAIN MJ: Oral chemotherapy: rationale and future directions. J. Clin. Oncol. (1998) 16(7)2557–2567.
   Google Scholar
• IYER L, RATAIN MJ: 5-Fluorouracil pharmacokinetics: causes for variability and strategies for modulation in cancer chemotherapy. Cancer Invest. (1999) 17(7)494–506.
   Google Scholar
• •An excellent review of the pharmacokinetics of 5-FU.
   Google Scholar
• META-ANALYSIS GROUP IN CANCER: Efficacy of intrave-nous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J. Gun. Oncol. (1998) 16(0:301–308.
   Google Scholar
• FRAILE RJ, BAKER LH, BUROKER TR, HORWITZ J, VAITKEVICIUS VK: Pharmacokinetics of 5-fluorouracil administered orally, by rapid intravenous and by slow infusion. Cancer Res. (1980) 40(7)2223–2228.
   Google Scholar
• ETIENNE MC, LAGRANGE JL, DASSONVILLE O, et al: Population study of dihydropyrimidine dehydroge-nase in cancer patients. J. Clin. Oncol. (1994) 12(102248–2253.
   Web of Science ®Google Scholar
• DIASIO RB, JOHNSON MR: Dihydropyrimidine dehydrogenase: its role in 5-fluorouracil clinical toxicity and tumor resistance. Clin. Cancer Res. (1999) 5(102672–2673.
   Web of Science ®Google Scholar
• HARRIS BE, SONG R, SOONG SJ, DIASIO RB: Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res. (1990) 50 (1):197–201.
   PubMed Web of Science ®Google Scholar
• DIASIO RB, LU Z: Dihydropyrimidine dehydrogenaseactivity and fluorouracil chemotherapy. J. Clin. Oncol (1994) 12(10:2239–2242.
   PubMed Web of Science ®Google Scholar
• NAGUIB FN, EL KOUNI MH, CHA S: Enzymes of uracilcatabolism in normal and neoplastic human tissues. Cancer Res. (1985) 45:5405–5412.
   PubMed Web of Science ®Google Scholar
• TATEISHI T, WATANABE M, NAKURA H et al.: Dihydropy-rimidine dehydrogenase activity and fluorouracil pharmacokinetics with liver damage induced by bile duct ligation in rats. Drug Metab. Dispos. (1999) 27 (6):651–654.
   PubMed Web of Science ®Google Scholar
• ETIENNE MC, CHERADAME S, FISCHEL JL et al.: Responseto fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity. J. Clin. Oncol. (1995) 13(7):1663–1670.
   PubMed Web of Science ®Google Scholar
• •Tumour biopsies were obtained from 62 head and neck cancer patients who received infusional 5-FU and DPD activity was assessed in the tumour and in normal tissue. The tumoural/non-tumoural DPD ratio correlated with response, suggesting that 5-FU catabolism in tumours plays a significant role in response to 5-FU.
   Google Scholar
• BECK A, ETIENNE MC, CHERADAME S et al. A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil. Eur. J. Cancer (1994) 10(22):1517–1522.
   Web of Science ®Google Scholar
• PORTER DJ, CHESTNUT WG, MERRILL BM, SPECTOR T:Mechanism-based inactivation of dihydropyrimidine dehydrogenase by 5- ethynyluracil. J. Biol. Chem. (1992) 267(8)5236–5242.
   Google Scholar
• •Describes the initial biochemical evaluation of eniluracil and related compounds.
   Google Scholar
• HEGGIE GD, SOMMADOSSI JP, CROSS DS, HUSTER WJ,DIASIO RB: Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine and bile. Cancer Res. (1987) 47(8)2203–2206.
   Google Scholar
• RUSTUM YM, HARSTRICK A, CAO S et al.: Thymidylatesynthase inhibitors in cancer therapy: direct and indirect inhibitors. J. Gun. Oncol. (1997) 15(1):389–400.
   Web of Science ®Google Scholar
• BAKER SD, DIASIO RB, O'REILLY S et al.: Phase I andpharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropy-rimidine dehydrogenase inactivator eniluracil. J. Clin. Oncol. (2000) 18(4):915–926.
   Google Scholar
• •This Phase I trial evaluated the 28-day schedule of eniluracil and oral 5-fluorouracil and established the recommended Phase II schedule and dose.
   Google Scholar
• SPECTOR T, HARRINGTON JA, PORTER DJ: 5-Ethynyluracil (776C85) inactivation of dihydropy-rimidine dehydrogenase in vivo. Biochem. Pharmacol (1993) 46:2243–2248.
   PubMed Web of Science ®Google Scholar
• BACCANARI DP, DAVIS ST, KNICK VC, SPECTOR T: 5-Ethynyluracil (776C85): a potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil. Proc. NMI Acad. Sci. USA (1993) 90 (23):11064–11068.
   PubMed Web of Science ®Google Scholar
• FISCHEL JL, ETIENNE MC, SPECTOR T, FORMENTO P, RENEE N, MILANO G: Dihydropyrimidine dehydroge-nase: a tumoral target for fluorouracil modulation. Clin. Cancer Res. (1995) 1(9):991–996.
   PubMed Web of Science ®Google Scholar
• •An in vitro assessment of the cytotoxicity of the eniluraci1/5-FU combination. Enhancement of 5-FU cytotox-icity by eniluracil occurred only in those cell lines that expressed the highest DPD activity.
   Google Scholar
• CAO S, RUSTUM YM, SPECTOR T: 5-Ethynyluracil(776C85): modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma. Cancer Res. (1994) 54 (6):1507–1510.
   PubMed Web of Science ®Google Scholar
• ARELLANO M, MALET-MARTINO M, MARTINO R, SPECTOR T: 5-Ethynyluracil (GW776): effects on the formation of the toxic catabolites of 5-fluorouracil, fluoroacetate and fluorohydroxypropionic acid in the isolated perfused rat liver model. Br. J. Cancer (1997) 76(9) :1170–1180.
   PubMed Web of Science ®Google Scholar
• DAVIS ST, JOYNER SS, BACCANARI DP, SPECTOR T:5-Ethynyluracil (776C85): protection from 5-fluorouracil-induced neurotoxicity in dogs. Biochem. Pharmacol. (1994) 48(2):233–236.
   PubMed Web of Science ®Google Scholar
• ADAMS ER, LEFFERT JJ, CRAIG DJ, SPECTOR T, PIZZORNOG: In vivo effect of 5-ethynyluracil on 5-fluorouracil metabolism determined by 19F nuclear magnetic resonance spectroscopy. Cancer Res. (1999) 59(1) 122–127.
   PubMed Web of Science ®Google Scholar
• CAO S, BACCANARI DP, RUSTUM YM et al.: a-fluoro-6-alanine: Effects on the antitumor activity and toxicity of 5-fluorouracil. Biochem. Pharmacol. (2000) 59:953–960.
   PubMed Web of Science ®Google Scholar
• SPECTOR T, CAO S, RUSTUM YM, HARRINGTON JA, PORTER DJ: Attenuation of the antitumor activity of 5-fluorouracil by (R)-5-fluoro- 5,6-dihydrouracil. Cancer Res. (1995) 55(6):1239–1241.
   PubMed Web of Science ®Google Scholar
• BAKER SD, KHOR SP, ADJEI AA et al.: Pharmacokinetic,oral bioavailability and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase. J. Clin. Oncol. (1996) 14(12):3085–3096.
   PubMed Web of Science ®Google Scholar
• •The first Phase I trial of oral 5-FU and eniluracil on a 5-day schedule.
   Google Scholar
• JANISCH L, MANI S, SCHILSKY RL et al: Phase I study todetermine the effects of food on the absorption of oral 776C85 (776) plus 5-fluorouracil (FU) in patients (pts) with advanced cancer. Proc. ASCO (1998) 17:224a.
   Google Scholar
• SCHILSKY RL, HOHNEKER J, RATAIN MJ et al: Phase Iclinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer. J. Clin. Oncol. (1998) 16(4):1450–1457.
   PubMed Web of Science ®Google Scholar
• HUMERICKHOUSE RA, DOLAN ME, HARAF DJ et al: PhaseI study of eniluracil, a dihydropyrimidine dehydroge-nase inactivator and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer. Clin. Cancer Res. (1999) 5 (2):291–298.
   PubMed Web of Science ®Google Scholar
• MEROPOL NJ, NIEDZWIECKI D, HOLLIS D, SCHILSKY RL,MAYER RJ: Phase II study of oral eniluracil, 5-fluorouracil and leucovorin in patients with advanced colorectal cancer. Cancer (2000) (Submitted).
   Google Scholar
• •This Phase II trial in patients with previously untreated colorectal cancer demonstrates that severe toxicity from eniluracil and 5-FU is inversely associated with creatinine clearance.
   Google Scholar
• AHMED FY, JOHNSTON SJ, CASSIDY J et al.: Eniluracil treatment completely inactivates dihydropyrimidine dehydrogenase in colorectal tumors. J. Clin. Oncol (1999) 17(8):2439–2445.
   PubMed Web of Science ®Google Scholar
• ••The only study to demonstrate the inactivation of DPD inhuman tumour tissue at clinical doses of eniluracil.
   Google Scholar
• MANI S, HOCHSTER H, BECK T eta].:A multicenter Phase II study to evaluate a 28-day regimen of oral fluorou-racil (5-FU) plus eniluracil (776C85) for the treatment of patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. (2000) (In Press)
   Google Scholar
• SCHILSKY R, BUKOWSKI R, BURRIS HI et al: A Phase IIstudy to evaluate a 5-day regimen of oral 5-flurouracil (5-FU) plus eniluracil with or without leucovorin for the treatment of patients with metastatic colorectal cancer. Ann. Oncol. (2000) 11 (5):415–420.
   PubMed Web of Science ®Google Scholar
• GOLDBERG RM, KUGLER JW, MAHONEY MR et al.: APhase II trial of 7 days of oral 776C85 plus five days of 5-fluorouracil (5-FU) in patients (pts) with metastatic colorectal cancer (M-CRC): A North Central Cancer Treatment Group Study. Proc. ASCO (2000) 19:245a.
   Google Scholar
• SMITH K, JOHNSTON S, O'BRIEN M, HICKISH T, HARRISD, BARTON C: High activity with eniluracil (776C85) and continuous low dose oral 5-fluorouracil (1 mg/m2 x 2 daily) as first-line chemotherapy in patients with advanced breast cancer: A Phase II study. Proc. ASCO (1999) 18:106a.
   Google Scholar
• BURRIS HA, RAVDIN R, GUTHEIL J et al.: Eniluraci1/5FUin anthracycline and taxane refractory breast cancer. Proc. ASCO (1999) 18:107a.
   Google Scholar
• RIVERA E, CHEVLEN E, ECKARDT J et al.: A Phase IIopen-label study to evaluate a 28-day oral regimen of 5-fluorouracil (5-FU) plus 776C85 for the treatment of patients with taxane and anthracycline resistant advanced breast cancer: preliminary results. Proc. ASCO (1998) 17:113a.
   Google Scholar
• JIANG W, LU Z, HE Y, DIASIO RB: Dihydropyrimidinedehydrogenase activity in hepatocellular carcinoma: implication in 5-fluorouracil-based chemotherapy. Clin. Cancer Res. (1997) 3(3):395–399.
   PubMed Web of Science ®Google Scholar
• BENSON AB, MITCHELL E, ABRAMSON N et al.: A multicenter, Phase II trial of oral eniluracil plus 5-FU in patients with inoperable hepatocellular carcinoma. Proc. ASCO (1999) 18:256a.
   Google Scholar
• KNOWLING M, BROWMAN G, COOKE A et al.: Phase IIstudy of eniluracil (776C85) and oral 5-fluorouracil (5-FU) in patients with advanced squamous cell head and neck cancer (HNC). Proc. ASCO (1999) 18:396a.
   Google Scholar
• DIASIO RB, BEAVERS TL, CARPENTER JT Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J. Clin. Invest. (1988) 81(1):47–51.
   Google Scholar
• HOUYAU P, GAY C, CHATELUT E, CANAL P, ROCHE H,MILANO G: Severe fluorouracil toxicity in a patient with dihydropyrimidine dehydrogenase deficiency. J. Natl. Cancer Inst. (1993) 85(19):1602–1603.
   PubMed Web of Science ®Google Scholar
• JOHNSON MR, HAGEBOUTROS A, WANG K, HIGH L, SMITH JB, DIASIO RB: Life-threatening toxicity in a dihydropyrimidine dehydrogenase- deficient patient after treatment with topical 5-fluorouracil. Clin. Cancer Res. (1999) 5(02006–2011.
   PubMed Web of Science ®Google Scholar
• VERWEIJ J: Rational design of new tumor activatedcytotoxic agents. Oncology (1999) 57 (Suppl. 0:9–15.
   Google Scholar
• MACKEAN M, PLANTING A, TWELVE C et al.: Phase land pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J. Clin. Oncol. (1998) 16(9)2977–2985.
   Google Scholar
• BUDMAN DR, MEROPOL NJ, REIGNER B et al: Prelimi-nary studies of a novel oral fluoropyrimidine carbamate: capecitabine. J. Clin. Oncol. (1998) 16(5):1795–1802.
   PubMed Web of Science ®Google Scholar
• VAN CUTSEM E, FINDLAY M, OSTERWALDER B et al:Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized Phase II study. J. Clin. Oncol. (2000) 18(6):1337–1345.
   PubMed Web of Science ®Google Scholar
• TWELVES C, HARPER P, VAN CUTSEM E et al.: A Phase IIItrial of Xeloda (Capecitabine) in previously untreated advanced/metastatic colorectal cancer. Proc. ASCO (1999) 18:263a.
   Google Scholar
• BLUM JL, JONES SE, BUZDAR AU et al.: Multicenter Phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J. Clin. Oncol. (1999) 17(2)485–493.
   Google Scholar
• MEROPOL NJ: Oral fluoropyrimidines in the treatment of colorectal cancer. Eur. J. Cancer (1998) 34(101509–1513.
   Web of Science ®Google Scholar
• HOFF PM, ROYCE M, MEDGYESY D, BRITO R, PAZDUR R:Oral fluoropyrimidines. Semin. Oncol. (1999) 26(6)640–646.
   Google Scholar
• PAZDUR R, LASSERE Y, DIAZ-CANTON E, BREADY B, HODH: Phase I trials of uracil-tegafur (UFT) using 5 and 28 days administration schedules: demonstration of schedule-dependent toxicities. AntiCancer Drugs (1996) 7(7)728–733.
   Google Scholar
• PAZDUR R, LASSERE Y, DIAZ-CANTON E, HO DH: Phase Itrial of uracil-tegafur (UFT) plus oral leucovorin: 28 day schedule. Cancer Invest. (1998) 16 (3):145–151.
   PubMed Web of Science ®Google Scholar
• PAZDUR R, LASSERE Y, RHODES V et al.: Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. J. Clin. Oncol. (1994) 12(10:2296–2300.
   PubMed Web of Science ®Google Scholar
• PAZDUR R, DOUILLARD JY, SKILLINGS JR, EISENBERG PD, DAVIDSON N, HARPER P: Multicenter Phase III study of 5-fluorouracil (5-FU) or UFT in combination with leucovorin (LV) in patients with metastatic colorectal cancer. Proc. ASCO (1999) 18:263a.
   Google Scholar
• RUSTUM YM, CAO S: New drugs in therapy of colorectal cancer: preclinical studies. Semin. Oncol. (1999) 26 (6):612–620.
   PubMed Web of Science ®Google Scholar
• MACDONALD JS: Oral fluoropyrimidines: a closer look at their toxicities. Am. J. Clin. Oncol. (1999) 22 (5):475–480.
   PubMed Web of Science ®Google Scholar
• SHIRASAKA T, NAKANO K, TAKECHI T et al. Antitumor activity of 1 M tegafu-0.4 M 5-chloro-2, 4-dihydro xypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res. (1996) 56(11) 2602–2606
   Google Scholar
• TAKECHI T, NAKANO K, UCHIDA J et al.: Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats. Cancer Chemother. Pharmacol. (1997) 39 (3):205–211.
   PubMed Web of Science ®Google Scholar
• ADJEI AA: A review of the pharmacology and clinical activity of new chemotherapy agents for the treatment of colorectal cancer. Br. J. Clin. Pharmacol. (1999) 48(3)265–277.
   Google Scholar
• PETERS GJ, AN GROENINGEN CJ, SCHOMAGE JH et al.:Phase I clinical and pharmacokinetic study of S-1, an oral 5-fluorouracil (5-FU)-based antineoplastic agent. Proc. ASCO (1997) 16:227a.
   Google Scholar
• TAGUCHI T, INUYAMA Y, KANAMARU R et al.: Phase I study of S-1. S-1 Study Group. Can To Kagaku Ryoho (1997) 24(15):2253–2264.
   Google Scholar
• FUJI M, KANZAKI J, SATAKE S, BAB S, INUYAMA Y: Early Phase II study of S-1 in patients with advanced head and neck cancer. Proc. ASCO (1996) 15:316.
   Google Scholar
• SAKATA Y, OHTSU A, HORIKOSHI N, SUGIMACHI K, MITACHI Y, TAGUCHI T: Late Phase II study of novel oral fluoropyrimidine anticancer drug 5–1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur. J. Cancer (1998) 34(10:1715–1720.
   Google Scholar
• FUJITA F, FUJITA M, INABA H, TAGUCHI T: Antitumor activity of BOF-A2, a new 5-fluorouracil derivative, against human cancers xenografted in nude mice by intermittent administration. Can To Kagaku Ryoho (1993) 20(2):223–228.
   PubMedGoogle Scholar
• LAMONT EB, SCHILSKY RL: The oral fluoropyrimidines in cancer chemotherapy. Clin. Cancer Res. (1999) 5 (9):2289–2296.
   PubMed Web of Science ®Google Scholar
• •A comprehensive review of the oral fluoropyrimidines.
   Google Scholar
• SUGIMACHI K, MAEHARA Y: Clinical effect of a new 5-FUderivative BOF-A2 for patients with advanced gastric cancer: A multicenter late Phase II study. Can. J. Inf. Dis. (1995) 6(Suppl. C):209C.
   Google Scholar
• KOBAYASHI S, MAEKAWA T, SAKAKIBARA N: Multicenter late Phase II study of BOF-A2 in colorectal cancer. Can. J. Infect. (1995) 6(Suppl. C):289C.
   Google Scholar
• TAGUCHI T, ABE O, TOMINAGA T et al. Clinical efficacy of a new 5-fluorouracil derivative, BOF-A2, in © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (2000) 9(7) advanced, recurrent breast cancer: a multicenter Phase II study. Non-serial; 18th International Congress of Chemotherapy (1993):322.
   Google Scholar
• GOLDBERG P: ODAC vote on CPT-11 changes standard of care for advanced colorectal cancer. The Cancer Letter (2000) 26(12):1–6.
   Google Scholar
• •A discussion of how the new standard of care for front-line treatment of colorectal cancer, combination therapy with 5-FU/leucovorin/CPT-11, will impact on the development of new drugs for colorectal cancer.
   Google Scholar
• SALTZ LB, LOCKER PK, PIROTTA N, ELFRING GL, MILLER LL: Weekly irinotecan (CPT-11), leucovorin (LV) and fluorouracil (FU) is superior to daily x 5 LV/FU in patients (PTS) with previously untreated metastatic colorectal cancer (CRC). Proc. ASCO (1999) 18:233a.
   Google Scholar
• DOUILLARD JY, CUNNINGHAM D, ROTH AD et al.: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet (2000) 355 (9209) :1041–1047.
   PubMed Web of Science ®Google Scholar